Abiopharma

🔍 Markel Stacy (Executive)

Company: Nuvation Bio Inc. (NUVB)

Report Date: 2026-06-23

Detailed Transactions and Holdings:

• Acquired 90,380 shares of Class A Common Stock at $1.87 per share (Direct)
  Date: 2026-06-23 | Code: M | equity_swap_involved: 0 | shares_owned_after: 122,971.00 | transaction_form_type: 4
• Acquired 34,620 shares of Class A Common Stock at $1.74 per share (Direct)
  Date: 2026-06-23 | Code: M | equity_swap_involved: 0 | shares_owned_after: 157,591.00 | transaction_form_type: 4
• Sold 125,000 shares of Class A Common Stock at $6.0255 per share (Direct)
  Date: 2026-06-23 | Code: S | equity_swap_involved: 0 | shares_owned_after: 32,591.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 90,380 shares of Stock Option (Right to Buy) at $1.87 per share (Derivative)
  Date: 2026-06-23 | Code: M | Expires: 2034-02-27 | equity_swap_involved: 0 | shares_owned_after: 409,620.00 | transaction_form_type: 4 | Footnotes: F3
• Sold 34,620 shares of Stock Option (Right to Buy) at $1.74 per share (Derivative)
  Date: 2026-06-23 | Code: M | Expires: 2030-01-21 | equity_swap_involved: 0 | shares_owned_after: 220,190.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Shares sold pursuant to a 10b5-1 plan dated December 4, 2025.
• F2: Price reported is a weighted-average sales price. The shares were sold at prices ranging from $6.00 to $6.085. The Reporting Person will provide, upon request, to the Securities and Exchange Commission, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
• F3: Option vests as to 25% on the one year anniversary of February 29, 2024, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.
• F4: Option vests as to 25% on September 30, 2020 and in equal monthly installments thereafter over the following three years, subject to Reporting Person's continuous service on each such vesting date.